ASR-3001

ASR-3001, also known as 5-methoxy-N-allyl-N-isopropyltryptamine (5-MeO-iPALT), is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 5-methoxytryptamine families which is under development for the treatment of psychiatric disorders.^{[5][1][2][3][6]} It is a close analogue of related psychedelic tryptamines like 5-MeO-DALT, 5-MeO-DiPT, and 5-MeO-MiPT.^[6] The drug is taken orally.^[1]

ASR-3001

Clinical data
Other names	ASR3001; 5-MeO-iPALT; 5-MeO-ALiPT; 5-Methoxy-N-allyl-N-isopropyltryptamine
Routes of administration	Oral[1]
Drug class	Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None
Pharmacokinetic data
Onset of action	≤15 minutes (as fast as 6–8 minutes)[1][2][3][4]
Duration of action	1.5–2.5 hours[4][1]
Identifiers
IUPAC name N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-2-amine
PubChem CID	166468733
Chemical and physical data
Formula	C17H24N2O
Molar mass	272.392 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)N(CCC1=CNC2=C1C=C(C=C2)OC)CC=C
InChI InChI=1S/C17H24N2O/c1-5-9-19(13(2)3)10-8-14-12-18-17-7-6-15(20-4)11-16(14)17/h5-7,11-13,18H,1,8-10H2,2-4H3 Key:MRWWDVFDOFUYKB-UHFFFAOYSA-N

Use and effects

ASR-3001 is said to be orally active, fast- and short-acting, and to induce "an internal psychedelic cognitive state [or head space] with little or no sensory [or visual] involvement".^[1][2][3][4] More specifically, it is said to have an absence of open-eye and closed-eye visuals.^[4] These properties are expected to allow ASR-3001 to serve as a potential "entry point" for people reluctant to undergo a fully immersive psychedelic experience that includes visuals.^[1][4] ASR-3001 is said to be internally psychedelic as opposed to entactogenic.^[4] Its dose range is 8 to 14 mg (or perhaps up to 10 mg), its onset is within 15 minutes or as fast as 6 to 8 minutes, and its duration is short at about 1.5 to 2.5 hours (90–150 minutes).^[1][2][3][4]

Interactions

See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

Pharmacodynamics

ASR-3001 acts as a non-selective agonist of the serotonin receptors.^[6] This includes of the serotonin 5-HT_2A, 5-HT_2B, 5-HT_1A, 5-HT_1B, and 5-HT₆ receptors, whereas other serotonin receptors, such as the serotonin 5-HT_2C receptor, were not described.^[6] Its EC₅₀Tooltip half-maximal effective concentration values were 9.85 nM at the serotonin 5-HT_2A receptor, 46.8 nM at the serotonin 5-HT_1B receptor, 87.4 nM at the serotonin 5-HT_2B receptor, 420 nM at the serotonin 5-HT₆ receptor, and 642 nM at the serotonin 5-HT_1A receptor.^[6] The drug was also a very weak serotonin reuptake inhibitor (IC₅₀Tooltip half-maximal inhibitory concentration = 6,840 nM), but did not inhibit norepinephrine or dopamine reuptake.^[6] It also showed little or no activity at various other sites.^[6]

Chemistry

Analogues

Other related analogues of ASR-3001 include ASR-3002 (2-Me-iPALT), ASR-3003 (iPALT), and ASR-3004 (PALT), among others.^[6]

Development

ASR-3001 is under development by the Nicholas V. Cozzi and Paul F. Daley and colleagues at the Alexander Shulgin Research Institute (ASRI).^[5][1][4] It was first described by 2023 and was patented the same year.^[1][6] As of early 2025, ASR-3001 is in the preclinical research stage of development.^[5][7] It is the ASRI's most advanced developmental candidate.^[4]

See also

• Substituted tryptamine
• List of investigational hallucinogens and entactogens
• ASR-2001 (2CB-5PrO)
• 5-MeO-EiPT
• 2C-T-17
• 4-HO-DiPT
• Luvesilocin (4-GO-DiPT)